Prime editing fixed a cystic fibrosis mutation with almost zero collateral damage

Key Findings

🫀 A 'one-shot' cholesterol fix is moving toward the clinic

• In-vivo base editing targeting PCSK9 — a gene that controls LDL cholesterol — is advancing through clinical trials as a potential single-treatment alternative to lifelong statin therapy.
• The review maps both the technology and the ongoing trial landscape, positioning this as one of the furthest-along cardiovascular gene-editing programs.

🧫 A hidden immune escape route runs through metabolism

• In-vivo CRISPR screens in mice identified DNMT3A — an epigenetic regulator — as a dual-function driver of tumor immune evasion: it silences TNF-receptor genes and, separately, activates cholesterol biosynthesis in tumor cells.
• The cholesterol byproduct zymosterol accumulates in tumor fluid and suppresses the killing capacity of CD8+ T cells, an effect independent of DNMT3A's primary enzymatic role.
• Blocking DNMT3A with antisense oligonucleotides improved response to immune checkpoint therapy in the mouse model.

💉 A new lipid nanoparticle hit 90% gene disruption at low dose

• Screening a library of ionizable lipids identified a formulation — LNPC12A9 — that disrupted a target gene in roughly 90% of human cells at 30 nM of CRISPR cargo, and ~60% at half that dose.
• The same particle delivered CRISPR components plus a repair template, achieving a 37.8% precision-editing rate via homology-directed repair — a notoriously difficult bar to clear with non-viral delivery.

🦠 A one-pot CRISPR test ID'd tuberculosis drug resistance in clinical samples

• TB-SCANER, a single-tube CRISPR-Cas12a diagnostic, detected Mycobacterium tuberculosis and profiled rifampicin resistance mutations simultaneously, matching Sanger sequencing for resistance calls and outperforming culture sensitivity (100% vs. 93.8%) in clinical samples.
• The assay uses RNA-based unlocking logic to run four detection channels at once — a multiplexing approach that sidesteps a longstanding limitation of CRISPR diagnostics.

🧠 A new viral vector reaches microglia with 90%+ specificity across species

• Researchers engineered an AAV platform with a compact 446-bp regulatory element and microRNA-based neuronal blocking that achieved greater than 90% microglial specificity after direct brain injection in mice — including in an Alzheimer's disease model.
• With a delivery assist, the same vector worked in rats, rhesus macaques, and human brain slices, enabling calcium imaging, chemogenetic control, and CRISPR editing specifically in microglia.

🌾 Genome editing recovered a tomato trait lost during domestication

• A targeted 13-base-pair deletion in the tomato SlGLK2 gene restored a reading frame that commercial breeding had accidentally broken, recovering chlorophyll accumulation and raising levels of sugars and tocopherols in ripe fruit.
• The fix used a temperature-tolerant Cas12a variant, demonstrating that editing can reverse domestication trade-offs rather than just introduce new traits.